Effect of Routine Surveillance Imaging on the Outcomes of Patients With Classical Hodgkin Lymphoma After Autologous Hematopoietic Cell Transplantation

Kapke, Jonathan; Epperla, Narendranath; Shah, Namrata; Richardson, Kristin; Carrum, George; Hari, Parameswaran; Pingali, Sai Ravi; Hamadani, Mehdi; Karmali, Reem; Fenske, Timothy S.

doi:10.1016/j.clml.2017.05.005

Cited by 8 publications

(7 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, whether this approach will truly result in an improved outcome for the lymphoma patients remains unknown, as indicated by the present systematic review. On the other hand, numerous previous studies have shown that early detection of disease recurrence in patients who achieved a complete remission by means of surveillance FDG-PET scans provides no survival benefit [9][10][11][12][13][14][15]. Although these results on surveillance FDG-PET imaging cannot be translated directly to the end-of-treatment setting, it demonstrated that early imaging-based detection of residual disease does not unambiguously translate into an OS improvement.…”

Section: Discussionmentioning

confidence: 97%

Systematic review on the value of end-of-treatment FDG-PET in improving overall survival of lymphoma patients

Adams

Kwee

2019

Ann Hematol

View full text Add to dashboard Cite

This study aimed to systematically review the value of end-of-treatment 18 F-fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET) in improving overall survival (OS) of lymphoma patients. Medline was systematically searched for (1) randomized trials comparing the OS of patients who underwent end-of-treatment FDG-PET to those without and FDG-PETbased end-of-treatment evaluation and for (2) non-randomized studies comparing the OS of patients who underwent end-oftreatment FDG-PET to a (historical) cohort of patients without an FDG-PET-based end-of-treatment evaluation. The Medline search revealed 6284 articles. However, none of these reported data on the value of end-of-treatment FDG-PET in improving OS of lymphoma patients. In conclusion, the present systematic review reveals that there is currently no study at all that evaluates the value of end-of-treatment FDG-PET in improving OS of lymphoma patients. As a result, it remains unknown whether end-oftreatment FDG-PET increases OS and in which lymphoma subtype these examinations are of particular value. Future studies are required to demonstrate its value in this setting before it can be recommended as an evidence-based diagnostic tool by guidelines on the use of imaging in lymphoma.

show abstract

Section: Discussionmentioning

confidence: 97%

Systematic review on the value of end-of-treatment FDG-PET in improving overall survival of lymphoma patients

Adams

Kwee

2019

Ann Hematol

View full text Add to dashboard Cite

show abstract

“…Other than the aforementioned report from Kapke et al [26], our study is the first in the literature to evaluate the utility of surveillance scanning in the posttransplant setting.…”

Section: Discussionmentioning

confidence: 84%

“…The only study in the literature that has specifically evaluated surveillance imaging in the transplant setting for HD was recently published by Kapke et al [26]. They evaluated 29 patients with HD who relapsed after transplant (relapses within the first 100 days were not evaluated).…”

Section: Discussionmentioning

confidence: 99%

Utility of Routine Surveillance Imaging for Hodgkin Disease following Autologous Transplant: Experiences from a Single Institution

et al. 2018

View full text Add to dashboard Cite

Background: Surveillance scans performed after autologous stem cell transplant (auto-HCT) for patients with Hodgkin disease (HD) have no proven survival benefit. Methods: We studied survival differences among patients with HD after auto-HCT whose recurrences were detected on clinical history and exam, versus those detected on routine surveillance scan. Results: Among the 98 patients with HD that underwent auto-HCT from 2000 to 2014 at our institution, 30 relapsed, of which 21 were detected radiologically and 9 clinically. There were no statistically significant differences in patient characteristics between the 2 groups. The median time to progression was 118 days for the clinical cohort and 284 days for the radiological cohort (p = 0.05). Median overall survival (OS) was 728 days for the clinical cohort, and was not reached for the radiological cohort (p = 0.02). Discussion: In our review, most patients with HD after auto-HCT were diagnosed radiologically. Patients whose relapse was diagnosed clinically were likely to be detected earlier and have a shorter OS. Patients with aggressive disease may be detected when clinically relevant, regardless of scanning. Routine scanning may not be necessary in the majority of patients with HD following auto-HCT.

show abstract

“…The rationale behind an FUIP following complete EwS remission is to benefit the outcome of patients with recurrence by detecting relapse at the earliest possible time, thereby inducing secondary therapy. Evidence for the value of this approach is a matter of debate in many malignant diseases and the results vary depending on the respective tumor entity . In patients with EwS, the required frequency of FU imaging is uncertain.…”

Section: Discussionmentioning

confidence: 99%

“…Evidence for the value of this approach is a matter of debate in many malignant diseases and the results vary depending on the respective tumor entity. [14][15][16] In patients with EwS, the required frequency of FU imaging is uncertain. Evidence that an FUIP provides benefit compared to a watch and wait for symptoms strategy is lacking.…”

Section: Discussionmentioning

confidence: 99%

Recurrence of Ewing sarcoma: Is detection by imaging follow‐up protocol associated with survival advantage?

Heinemann

Ranft

Langer

et al. 2018

Pediatric Blood & Cancer

View full text Add to dashboard Cite

show abstract

Effect of Routine Surveillance Imaging on the Outcomes of Patients With Classical Hodgkin Lymphoma After Autologous Hematopoietic Cell Transplantation

Cited by 8 publications

References 19 publications

Systematic review on the value of end-of-treatment FDG-PET in improving overall survival of lymphoma patients

Systematic review on the value of end-of-treatment FDG-PET in improving overall survival of lymphoma patients

Utility of Routine Surveillance Imaging for Hodgkin Disease following Autologous Transplant: Experiences from a Single Institution

Recurrence of Ewing sarcoma: Is detection by imaging follow‐up protocol associated with survival advantage?

Contact Info

Product

Resources

About